Literature DB >> 31591480

MHC class I dysfunction of glioma stem cells escapes from CTL-mediated immune response via activation of Wnt/β-catenin signaling pathway.

Wei Yang1, Yanyan Li2, Ruoling Gao3, Zenghe Xiu3, Ting Sun4.   

Abstract

Glioma stem cells (GSCs) decrease T cells cognition and evade systemic immunosurveillance via downregulations or defects of major histocompatibility complex class I (MHC-I) molecule and antigen-processing machinery (APM) components. Improvement of tumor surface antigens of GSCs may be effective strategy to trigger an adaptive immune response and activate cytotoxic T cells (CTLs) to eliminate glioma. In this study, our data indicated that downregulations of MHC-I and APM components expressions were associated with Wnt pathway activation in GSCs. Histone deacetylases (HDAC) inhibition improved MHC-I and APM components expressions, which could be partly reverted by Wnt pathway activation. Blocking CTLs-mediated killing decreased the anti-tumor effect of tumor lysate vaccine. The enhancement of T cells immune response resulting from HDAC inhibition was dependent on CTLs cognition on tumor antigens presented by upregulated MHC-I molecule in GSCs. These data suggest that suppression of stemness pathway may be effective for GSCs-based immunotherapy against immune-escaped tumors.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31591480     DOI: 10.1038/s41388-019-1045-6

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  3 in total

1.  IFN-gamma-induced recognition of the antigen-processing variant CMT.64 by cytolytic T cells can be replaced by sequential addition of beta 2 microglobulin and antigenic peptides.

Authors:  W A Jefferies; G Kolaitis; R Gabathuler
Journal:  J Immunol       Date:  1993-09-15       Impact factor: 5.422

2.  MiR-146b-5p overexpression attenuates stemness and radioresistance of glioma stem cells by targeting HuR/lincRNA-p21/β-catenin pathway.

Authors:  Wei Yang; Hongquan Yu; Yueming Shen; Yingying Liu; Zhanshan Yang; Ting Sun
Journal:  Oncotarget       Date:  2016-07-05

3.  Targeting transferrin receptor delivery of temozolomide for a potential glioma stem cell-mediated therapy.

Authors:  Ting Sun; Haibin Wu; Yanyan Li; Yulun Huang; Lin Yao; Xionghui Chen; Xiaoxiao Han; Youxin Zhou; Ziwei Du
Journal:  Oncotarget       Date:  2017-08-10
  3 in total
  29 in total

Review 1.  Towards targeting of shared mechanisms of cancer metastasis and therapy resistance.

Authors:  Felix Weiss; Douglas Lauffenburger; Peter Friedl
Journal:  Nat Rev Cancer       Date:  2022-01-10       Impact factor: 60.716

Review 2.  Reprogramming the tumor microenvironment to improve the efficacy of cancer immunotherapies.

Authors:  Jabar A Faraj; Ali Jihad Hemid Al-Athari; Sharaf El Din Mohie; Iman Kareem Kadhim; Noor Muhsen Jawad; Weaam J Abbas; Abduladheem Turki Jalil
Journal:  Med Oncol       Date:  2022-09-29       Impact factor: 3.738

Review 3.  Mechanism and therapeutic potential of tumor-immune symbiosis in glioblastoma.

Authors:  Lizhi Pang; Fatima Khan; Amy B Heimberger; Peiwen Chen
Journal:  Trends Cancer       Date:  2022-05-24

4.  Infiltrating natural killer cells bind, lyse and increase chemotherapy efficacy in glioblastoma stem-like tumorospheres.

Authors:  Barbara Breznik; Meng-Wei Ko; Christopher Tse; Po-Chun Chen; Emanuela Senjor; Bernarda Majc; Anamarija Habič; Nicolas Angelillis; Metka Novak; Vera Župunski; Jernej Mlakar; David Nathanson; Anahid Jewett
Journal:  Commun Biol       Date:  2022-05-10

Review 5.  Immunogenic cell death in colon cancer prevention and therapy.

Authors:  Hang Ruan; Brian J Leibowitz; Lin Zhang; Jian Yu
Journal:  Mol Carcinog       Date:  2020-03-25       Impact factor: 4.784

6.  Tumor cell and immune cell profiles in primary human glioblastoma: Impact on patient outcome.

Authors:  María González-Tablas Pimenta; Álvaro Otero; Daniel Angel Arandia Guzman; Daniel Pascual-Argente; Laura Ruíz Martín; Pablo Sousa-Casasnovas; Andoni García-Martin; Juan Carlos Roa Montes de Oca; Javier Villaseñor-Ledezma; Luis Torres Carretero; Maria Almeida; Javie Ortiz; Adelaida Nieto; Alberto Orfao; María Dolores Tabernero
Journal:  Brain Pathol       Date:  2021-02-13       Impact factor: 6.508

7.  Effect of Licochalcone-A Combined with Rab23 Gene on Proliferation of Glioma U251 Cells.

Authors:  Yindong Mu; Jianjiang Dong; Hong Cui; Jiangping Hu; Jun Liang; Lei Yan
Journal:  Evid Based Complement Alternat Med       Date:  2022-04-22       Impact factor: 2.650

8.  Immunostimulatory bacterial antigen-armed oncolytic measles virotherapy significantly increases the potency of anti-PD1 checkpoint therapy.

Authors:  Eleni Panagioti; Cheyne Kurokawa; Kimberly Viker; Arun Ammayappan; S Keith Anderson; Sotiris Sotiriou; Kyriakos Chatzopoulos; Katayoun Ayasoufi; Aaron J Johnson; Ianko D Iankov; Evanthia Galanis
Journal:  J Clin Invest       Date:  2021-07-01       Impact factor: 14.808

Review 9.  Deubiquitinating Enzymes Orchestrate the Cancer Stem Cell-Immunosuppressive Niche Dialogue: New Perspectives and Therapeutic Potential.

Authors:  Jun-Nan Guo; Bai-Rong Xia; Shen-Hui Deng; Chang Yang; Ya-Nan Pi; Bin-Bin Cui; Wei-Lin Jin
Journal:  Front Cell Dev Biol       Date:  2021-06-09

Review 10.  HLA class I loss in colorectal cancer: implications for immune escape and immunotherapy.

Authors:  Per Anderson; Natalia Aptsiauri; Francisco Ruiz-Cabello; Federico Garrido
Journal:  Cell Mol Immunol       Date:  2021-01-20       Impact factor: 22.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.